Amulirafusp alfa

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameAmulirafusp alfa
Drug Alias NameIMM-0306IMC-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD20 +[4] 
TargetsB-lymphocyte antigen CD20Cluster of differentiation 47
Therapy Area/IndicationsLupus Erythematosus, SystemicNephrosisLupus Nephritis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesYiming Kell Biomedical Technology (Shanghai) Co LtdImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicNephrosisLupus Nephritis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A